

Index

a

- ablation techniques 656
- absent contractility 162
- accidental/intentional ingestion of
 - caustic agents 757
- acetic acid (AA) 149
- achalasia 6, 54, 139–140, 161, 249, 265, 278–279, 636–637, 826–828
 - clinical manifestations of 252
 - definition of 249
 - diagnosis 252–254
 - Eckardt score for 28
 - endoscopic botulinum toxin
 - injection 279
 - endoscopic pneumatic dilation 279–280
 - endoscopic stenting 280
 - epidemiology of 249
 - esophagectomy, for end-stage achalasia 259
 - foreign body ingestion 713
 - guidelines for 260
 - incidence of 27
 - initial treatment, symptoms reoccur for 259
 - laparoscopic Heller myotomy
 - for 256
 - manometric subtypes of 251
 - minimally invasive esophagectomy 287
 - pathophysiology of 27–28, 249–252
 - per-oral endoscopic myotomy 30, 258–259, 280–283
 - mucosal closure in 282
 - mucosal incision in 281
 - myotomy in 281–282
 - outcomes of 282–283
 - vs. pneumatic dilation 283
 - submucosal tunneling in 281
 - technique 281
 - pharmacological treatment of
 - botulinum toxin A 254
 - smooth muscle relaxants 254
 - pneumodilation for 255–256
 - primary 139, 140
 - prognosis of 259
 - screen/not for esophageal cancer 260
 - secondary 139, 140
 - subtypes 162, 163
 - surgical esophageal myotomy
 - Heller myotomy vs. pneumatic dilation 286–287
 - Heller myotomy vs. POEM 285–286
 - outcomes 284–285
 - technique 283–286
 - treatment 254–259
- achalasia severity questionnaire (ASQ) 254
- acid burn, GERD 382–383
- acid-hypersensitive esophagus 193
- acid-induced injury 758–759
- acid pocket 351
- acid production, for GERD
 - management 432–433
- acid reflux 195
- acid-sensing ion channels (ASIC) 22
- acid suppression 586–587
- acid-suppressive therapy 594
 - for GERD management 432
 - with PPI 270
- acquired immunodeficiency syndrome (AIDS) 736
- acrokeratosis neoplastica 798
- acute esophageal GVHD 228
- acute esophageal necrosis 836
- adenocarcinomas 133
 - with submucosal invasion 234–235
- adenoma 128
- adequate contractile reserve 165
- adherens junctions (AJs) 378–380
- adjuvant chemotherapy 656
- advanced esophageal carcinomas 133
- aerophagia 498–500
 - assessment of 499
 - behavioral treatment 499–500
- age-related esophageal manometric changes 806
- aging population, esophageal disorders 804–836
 - achalasia 826–828
 - acute esophageal necrosis 836
 - central nervous system diseases 814–821
 - chronic saphagitis dessicans 836
 - distal esophageal spasm and related disorders 828–829
 - dysphagia 813–814
 - EGJO 829–830
 - esophageal carcinoma 832
 - esophageal dysphagia 825
 - esophageal physiology, changes in 805–808
 - gastroesophageal reflux disease-related physiology, changes in 809–811
 - idiopathic upper esophageal sphincter dysfunction 821–822
 - intramural esophageal pseudodiverticulosis 836
 - Jackhammer esophagus 830
 - local structural lesions 822

- medication-induced esophageal injury 835
 - motility 805–808
 - oropharyngeal dysphagia, general approach 824–825
 - peptic strictures 832–833
 - pharyngoesophageal function 805
 - rings or webs 833–834
 - scleroderma 830–831
 - sensory function 808
 - sloughing esophagitis 836
 - spontaneous hemorrhage 836
 - spontaneous intramural hematoma of esophagus 836
 - treatment differences 811–813
 - vascular compression 834–835
 - Zenker's diverticulum 822–824
 - airway manifestations of reflux 567
 - asthma and GERD 570–573
 - clinical presentations and evaluation 569–570
 - idiopathic pulmonary fibrosis 573–575
 - lung transplantation 575–577
 - pathophysiology 567–569
 - therapy 570
 - alcohol and GERD management 430
 - aldehyde dehydrogenase mutations 636
 - alendronate 125, 730
 - alkali-induced injury 757–758
 - alkaline reflux 198
 - esophagitis 127
 - allergic reaction 616
 - allodynia 21
 - Alzheimer's disease (AD) 816
 - ambulatory bilirubin monitoring (Bilitec) 405–408
 - ambulatory monitoring for reflux 188
 - esophageal bilirubin monitoring 198–199
 - clinical relevance of 198–199
 - technical aspects of 198
 - esophageal pH-impedance monitoring 194–198
 - esophageal pH monitoring systems 188–189
 - catheter-based pH monitoring 189–190
 - clinical relevance of 192–194
 - pH monitoring off therapy 192–193
 - pH monitoring on therapy 193–194
 - proximal pH recordings 190–191
 - wireless pH monitoring 191–192
 - symptom association analysis 199–203
 - ambulatory reflux monitoring 339–341
 - on acid suppression 342–343
 - metrics 340–341
 - phenotypes 341
 - reflux hypersensitivity 341
 - symptoms and ambulatory reflux events 341
 - systems 340
 - with/without acid suppression 340
 - amyloidosis 320–322
 - amyotrophic lateral sclerosis (ALS) 821
 - Angelchik prosthesis 616
 - anidulafungin (Eraxis) 742
 - animal models using lithium batteries 724
 - antacids for GERD management 431
 - anti-acetylcholine receptor (AChR) antibodies 820
 - antibiotics 730
 - anti-IgE 696
 - anti-IL-4 receptor 699
 - anti-IL-5 698
 - anti-IL-13 698–699
 - antimicrobial prophylaxis 736
 - anti-reflux barrier
 - endoscopic assessment of 339
 - to gastroesophageal reflux disease 343
 - anti-reflux mucosectomy (ARMS) technique, for GERD treatment 484–486
 - anti-reflux surgery 602
 - in asthma 572–573
 - for GERD 591–599
 - application of surgical therapy 595
 - Barrett's and development of esophageal adenocarcinoma 598
 - candidates for 594–595
 - Collis gastroplasty 598
 - hiatal hernias 598
 - intestinal metaplasia development 597
 - longevity of 596
 - on low-grade dysplasia 598
 - surgical therapy 595
 - principles of 474
 - antireflux therapies
 - in IPF 574–575
 - in lung transplantation 576–577
 - antiretroviral therapy (ART) 736
 - antisecretory agents *see* potassium-competitive acid blockers (P-CABs)
 - antithymocyte globulin 737
 - aortoesophageal fistulae 142
 - apical junctional complex (AJC) 378–380
 - appendectomy 592
 - argon plasma coagulation (APC) 523, 656
 - A ring 352
 - ARMS technique *see* anti-reflux mucosectomy (ARMS) technique
 - arteria lusoria 716
 - aspergillosis 743
 - aspiration pneumonia 44, 47
 - asthma and GERD 570–573
 - asthma multidose inhaler (MDI) 696
 - atrophic cardiac-type mucosa 232
 - atrophic gastric fundic mucosa 512
 - Auerbach's plexus 70
 - auto-florescence imaging (AFI) 148
 - autoimmune connective tissue disorders 796–798
 - autoimmune mucocutaneous blistering disorders (AMBD) 789–794
 - autoimmune mucocutaneous intraepithelial blistering disorders (AMIEBD) 789–794
 - autoimmune mucocutaneous subepithelial blistering disorders (AMSEBD) 789–794
 - automated impedance manometry (AIM) 164
 - automatic implantable cardioverter defibrillators (AICDs) 617
 - azole resistance 742–743
- b**
- backyard barbeque syndrome 298
 - baclofen 316
 - for GERD management 432
 - for rumination syndrome 57
 - bacterial and fungal infections 737

- bacterial esophagitis 222, 748–749
- balloon dilators 535
- band EMR technique 653, 654
- barium esophagogram 6–7, 288, 306, 313
- barium swallow 252
- Barrett's esophagus (BE) 117, 120–121, 126, 127, 136, 148, 230–240, 319, 396–398, 510–524, 597
 - adherence to surveillance
 - guidelines 517
 - advanced imaging techniques 517
 - BE-related neoplasia 236
 - chromoendoscopy 149, 517–518
 - clinical features 515
 - definition of 230, 510–511
 - diagnostic challenges 235–236
 - diagnostic criteria 510–511
 - dysplasia 514
 - and neoplasm 232
 - endoscopic diagnosis 515–516
 - endoscopic mucosal resection,
 - evaluation of 235
 - endoscopic submucosal dissection
 - specimens 235
 - endoscopic surveillance 516–517
 - epidemiology 511
 - esophageal cytology specimens,
 - evaluation of 236
 - esophageal mucosal biopsy,
 - diagnosis in 230–235
 - genetic and epigenetic alterations 513
 - H. pylori* 422
 - management 516–519
 - mucosal ablation therapy 235–236
 - neoplastic progression 513–514
 - in older patients 810–811
 - pathogenesis of metaplasia 511–513
 - Prague Classification 510, 511
 - risk factors and protective factors
 - 511, 512
 - screening 516
 - squamous cell carcinoma 236–239
 - squamous-to-columnar metaplasia
 - 510
 - surveillance after EET 523–524
 - symptoms, hernia size 610–611
 - treatment 519–523
 - volumetric laser endomicroscopy
 - for 150–153
- Barrett's International NBI Group (BING) 518
- basaloid squamous cell carcinoma 237
- basal pressures, to upper esophageal sphincter 67
- Bazex syndrome (acrokeratosis neoplastica) 798
- Behcet's disease (BD) 323, 798
- benign esophageal tumors 642–644
- Bernstein test 19
- bethanechol 273
- bile acids
 - Barrett's esophagus 396–398
 - epithelial triple threat 376–377
 - erosive, non-erosive reflux disease
 - 400–401
 - esophageal adenocarcinoma 396–398
- bile monitoring 208–209
- bilirubin reflux 198
- biofeedback therapies
 - for esophageal hypersensitivity 26
 - for rumination syndrome 56
- bisphosphonates 730–731
- blastomycosis 743
- body mass index (BMI) and GERD
 - symptoms 430
- Boerhaave's syndrome 305
- Bolster technique 299
- bolus exposure time (BET) 573, 574
- bolus reflux 195
- botox injection 270–271
- botulinum toxin A injection 82, 289
 - for achalasia 254
 - endoscopic, for achalasia 279
 - for esophageal chest pain 30
- Boyle's Law 56
- branchial cleft fistulae 107–108
- branchial pouch sinuses 107–108, 112
- B ring 352
- bronchoalveolar lavage fluid (BALF)
 - 569, 570
- bulimia 54
- bullous diseases 226–227
- bullous pemphigoid 226
- bullous systemic lupus erythematosus (BSLE) 792
- bupirone 316
 - for rumination syndrome 57
- button batteries 723–724, 771
- C**
 - calcium channel blockers (CCBs) 29, 270
 - calibrated endoscopic myotomy 161
 - Cameron lesions 349
 - Candida* esophagitis 121–122, 127, 220, 737
 - Candida* pharyngitis 113
 - Candida* species 737, 739–743
 - azoles 741
 - clinical manifestations 739
 - complications 739
 - cytochrome P-450-dependent
 - interference 741
 - diagnosis 739–740
 - drug resistance 742–743
 - echinocandins 742
 - empirical antifungal therapy 740
 - epidemiology 738
 - pathologic appearance 738–739
 - polyene antibiotics 742
 - prophylactic use of ketoconazole or nystatin 742
 - prophylaxis 741
 - serologic tests 740
 - skin testing 740
 - systemic antifungal therapy 740
 - treatment 740–742
 - cap EMR technique 653
 - capsaicin 76
 - carbon dioxide insufflation 720
 - carcinoma cuniculatum 237, 238
 - cardiac mucosa 512, 513
 - cardiac rosette 115
 - cardiac septal occluder 782
 - caspofungin (Cancidas) 742
 - catecholamines 76
 - catheter-based pH monitoring
 - 189–190
 - electrodes 189
 - interpretation of 190
 - practical aspects of 189–190
 - caustic esophagitis 126–127, 133
 - caustic ingestion in children 772
 - caustic injuries of esophagus
 - acid-induced injury 758–759
 - clinical presentation 759–760
 - delayed complications 763–764
 - incidence 757
 - initial evaluation 760–762
 - management 762–763
 - nutrition 763–764
 - pathophysiology 757–758
 - severity, determinants of 759
 - signs and symptoms 759, 760
 - specific substances, risks of 759

- stabilization and supportive care 763
 - steroids 763
 - surgical approach 764
 - caustic strictures 543–544
 - cell proliferation, pH conditions 399
 - central nervous system diseases 814–821
 - central organizing center 41
 - cervical esophageal perforation 143
 - cervical esophageal webs 108, 110, 116
 - cervical lymphadenopathy 111
 - chemoattractant receptor-homologous molecule on T_H2 cells (CRTH2) 697–698
 - chemotherapy 732, 737
 - chemotherapy-induced esophagitis 222–223, 732
 - chest pain 8–9, 252
 - chest radiography 760
 - Chicago Classification 161, 162, 265, 278, 289
 - of esophageal motility disorders 157, 266
 - cholecystectomy 592
 - cholecystokinin (CCK) 80
 - CCK-A receptor 367
 - chondromas 110
 - chromoendoscopy 149, 637
 - chronic cough 504–505
 - chronic esophageal GVHD 228
 - chronic lye stricture 133
 - chronic esophagitis *dessicans* 836
 - cirrhosis 665
 - cisapride 273
 - clouse plots 155
 - Cobblestoning of posterior pharynx 557
 - cognitive-behavioral therapy (CBT), for esophageal hypersensitivity 25, 26
 - collagen vascular diseases 227–228
 - columnar blue cells 231
 - columnar mucosae 512
 - compartmentalized pressurization 160
 - complete remission of intestinal metaplasia (CRIM) 523, 656
 - complex strictures 541–543
 - computed tomography (CT) scan 760–762
 - concomitant laparoscopic hernia repair, and TIF procedure 481–482
 - confocal laser endomicroscopy (CLE) 149–150, 382, 386, 518–519, 637
 - endoscope-based 150
 - probe-based 150
 - congenital diaphragmatic hernias 350
 - connective tissue disorders
 - fibromyalgia 318
 - mixed connective tissue disease 316
 - myositis 316–317
 - Sjogren's syndrome 317–318
 - systemic lupus erythematosus 318
 - systemic sclerosis (scleroderma) 312–316
 - constrictor muscle paresis 114
 - contractile deceleration point (CDP) 159–160
 - contrast esophagogram 774
 - for esophageal diverticula 306–307
 - coping skills training, for esophageal hypersensitivity 26
 - corrosive esophagitis 224
 - corticosteroids 737
 - corticotropin-releasing hormone (CRH) 24
 - Cowdry's type A inclusion bodies 220–221
 - CREST syndrome 6
 - cricopharyngeal achalasia (CA) 816
 - cricopharyngeal bars 46, 539
 - cricopharyngeal diverticulum 307–309
 - cricopharyngeal myotomy (CPM) 46, 47, 815–816, 818
 - cricopharyngeus/cricopharyngeal (CP) muscle 539
 - Crohn's disease (CD) 226, 322–323
 - crural diaphragm, neural pathway 362–363, 366
 - cryotherapy delivery systems 523
 - cutaneous diseases of esophagus, inflammatory mucocutaneous disorders 789–799
 - cutaneous paraneoplastic disorders
 - associated with esophageal carcinoma 798–799
 - cylindrical batteries 724
 - CYP3A4 434
 - CYP2C19 434
 - cytokine sizzle, GERD 384–388
 - cytomegalovirus (CMV) esophagitis 123, 129, 221–222, 736, 745–747
- d**
- deglutitive aspiration 43
 - DeMeester's score 190
 - deoxycholic acid (DCA) 401
 - dermatologic and collagen vascular diseases 226–227
 - dermatomyositis (DM) 101, 316, 317, 797, 819
 - dexlansoprazole 434
 - diabetes mellitus (DM) 318–319
 - diaphragmatic breathing 55–56
 - diaphragm, to lower esophageal sphincter 82–83
 - dietary and nutritional factors 636
 - diet therapy 695–696
 - diffuse esophageal spasm (DES) 28, 140, 141, 288
 - diffuse idiopathic skeletal hyperostosis (DISH) 822
 - digital chromoendoscopy 149
 - dilations of intercellular space (DIS) 182
 - diltiazem 29
 - direct immunofluorescence (DIF) 226
 - disorders associated with primary HIV infection 750
 - disorders of laryngeal hyper-responsiveness 503–505
 - distal contractile integral (DCI) 159
 - distal esophageal spasm (DES) 28, 162, 175, 268–269, 288–289, 817
 - and related disorders 828–829
 - treatment of 270–271
 - distal latency (DL) 159–160, 268
 - diverticula, esophagus, radiology of 135
 - esophageal intramural pseudodiverticula 138–139
 - pulsion diverticula 138
 - traction diverticula 138, 139
 - Dor antireflux procedure 257
 - Dor fundoplication 286, 309
 - dorsal motor nucleus of the vagus (DMNV) 63, 366
 - dorsal swallowing group (DSG) 62
 - downhill varices 141
 - Down syndrome (DS) 319–320
 - doxycycline 123
 - induced esophagitis 730
 - drug-induced esophagitis 123, 125, 131, 223–224
 - duodenogastroesophageal reflux (DGER) 198, 208
 - acid and pepsin 394–396
 - duodenal contents role
 - Barrett's esophagus 396–398

- duodenogastroesophageal reflux (DGER) (*cont'd*)
 - erosive, non-erosive reflux disease 400–401
 - esophageal adenocarcinoma 396–398
 - in vitro 398–400
 - in humans
 - ambulatory bilirubin monitoring 405–408
 - ambulatory pH monitoring 404–405
 - bariatric surgery 410
 - endoscopy 402
 - esophageal aspiration 403
 - gastric measurements 402–403
 - impedance-pH monitoring 408–409
 - scintigraphy 403
 - and symptoms 409–410
 - laryngeal and respiratory mucosa 401–402
 - medical and surgical treatment 410–412
 - duplication cysts 130, 136
 - dynamic failure 468
 - dyskeratosis congenita 798
 - dysmotility 27–29
 - achalasia
 - Eckardt score for 28
 - incidence of 27
 - pathophysiology of 27–28
 - distal esophageal spasm 28
 - hypercontractile (jackhammer) esophagus 28–29
 - dysphagia 5–7, 101, 252, 273, 313, 318, 319, 324, 492–498, 593, 743, 813–814, 819, 820
 - behavioral strategies 498
 - with cricopharyngeal myotomy 815–816
 - diagnostic approach 6–7
 - direct swallowing treatment 497–498
 - esophageal 5, 6
 - evaluation of 7
 - indirect swallowing treatment 495–497
 - multiphase swallow assessment 493–495
 - non-invasive methods 815
 - oropharyngeal swallow assessment 5, 493
 - patient history and physical examination 6
 - postoperative 618
 - rehabilitation principles 495
 - swallowing physiology 492–493
 - symptoms of 5–7
 - treatment of 317
 - dysphagia aortica 834
 - dysphagia symptom questionnaire (DSQ) 685
 - dysplasia 232, 514
 - definition of 233
 - indefinite for 233
 - negative for 232
 - positive for 233–234
 - dysplastic Barrett's esophagus, treatment 521–523
- e**
- early esophageal cancer 131, 132, 136
 - Eckardt score 13, 254, 279
 - edema 114, 732
 - EGJ distensibility index (EGJ-DI) 267
 - Ehlers-Danlos syndrome (EDS) 320
 - eicosanoids 76
 - electronic chromoendoscopy 149, 518
 - EndoCinch suturing device 483
 - endocrine disorders 318
 - diabetes mellitus 318–319
 - thyroid disease 319
 - Endoflip® 254, 259, 267, 273, 280, 281, 285
 - endoluminal fundoplication (ELF) 483–484
 - endoscope-based CLE 150
 - endoscopic ablative techniques 522
 - of non-resectable EAC 656
 - endoscopic anti-reflux procedures, GERD 487
 - endoscopic application of polyglycolic acid sheets 782
 - endoscopic clips 777–779
 - endoscopic eradication therapy (EET) 521
 - endoscopic management 775–776
 - endoscopic mucosal dissection or surgery 670
 - endoscopic mucosal resection (EMR) 218, 235, 521, 640, 652, 653
 - endoscopic myotomy of cricopharyngeus 773
 - endoscopic stapled esophagodiverticulostomy 308
 - with CP myotomy 308
 - endoscopic stenting 280
 - endoscopic submucosal dissection (ESD) 218, 522, 654, 655
 - specimens 235
 - endoscopic suturing 780–781
 - for GERD 483–487
 - endoscopic treatment of esophageal cancer 651–658
 - lymph node metastases 651, 652
 - nodal stage 651, 652
 - T1a (mucosal) adenocarcinoma 656–658
 - T1b (submucosal) adenocarcinoma 658
 - techniques 652–655
 - endoscopic ultrasound
 - examination 638
 - endoscopic vacuum therapy 782
 - endoscopy 252, 313, 318, 320, 760
 - duodenogastroesophageal reflux 402
 - preparation 719
 - end-stage achalasia, esophagectomy for 259
 - enkephalins 76
 - ENT complaints in GERD 554–563
 - confirmatory testing for EER/LPR 559–561
 - cost 563
 - diagnosis 555–557
 - esophagogastrroduodenoscopy 561
 - laryngoscopy 557–559
 - management 561–562
 - pathophysiology 555
 - prevalence 555
 - surgical therapy 562
 - EoE Diagnostic Panel (EDP) 685
 - EoE Endoscopic Reference Score (EREFS) 685
 - EoE Histologic Severity Score (EoE-HSS) 685
 - EoE Symptom Activity Index (EEsAI) 685
 - eosinophilic esophagitis (EoE) 6, 125, 132, 184, 322, 540–541, 722, 834
 - barium esophagram 686
 - chronic allergen/immune-mediated condition 683
 - clinical features 686–690

- Cytosponge 685
- definition 681
- diagnosis 683–686
- disease activity measures 685–686
- endoluminal ultrasonography 688
- endoscopy 686–688
- eosinophilic inflammation 684
- epidemiology 681–683
- esophageal manometry 688–689
- histology 690–691
- imaging techniques 685
- impedance planimetry 689
- incidence 682
- natural history 692–693
- pathogenesis 685, 691–692
- phenotypes 689
- prevalence 682
- research networks 681
- with ringed esophagus 132
- risk factors 682
- with small-caliber esophagus 132
- symptoms 686
- therapeutic endpoints 693–694
- treatment 693–701
- eosinophilic gastroenteritis 225
- eosinophilic microabscesses 224
- epidermolysis bullosa acquisita (EBA) 791–792
- epiglottic tilt 100, 101
 - asymmetric 104
- epiphrenic diverticulum 304, 305, 309–310
- epithelial defense
 - esophageal tissue resistance 378–381
 - functional components 381
- epithelial necrosis 795
- epithelial-to-mesenchymal transition (EMT) 400
- erosion of peri-esophageal implant 616
 - safety data on 616–617
- erosive esophagitis 568
 - healing of 434, 435
- erosive reflux disease 400–401
- esophageal acid exposure 190
- esophageal adenocarcinoma (EAC) 396–398, 510
 - H. pylori* 422–423
- esophageal-airway fistula 142
- esophageal bilirubin monitoring 198–199
 - clinical relevance of 198–199
 - technical aspects of 198
- esophageal body 805–806
 - anatomy 70–71
 - innervation of 70–71
 - smooth muscle in 71
 - striated muscle in 71
 - structure of 70–71
- esophageal cancer 131–134, 136, 137, 764, 832
 - incidence 635
 - mortality rates 635
- esophageal chest pain (ECP) 18
 - diagnostic and treatment algorithm for 22
- dysmotility 27–29
- epidemiology of 18–19
- esophageal hypersensitivity
 - allodynia 21
 - esophageal injury, mechanisms of 23
 - hyperalgesia 21
 - non-pharmacologic therapies for 25–27
 - pathophysiology of 21–24
 - peripheral and central sensitization in 23
 - pharmacologic therapies for 24–25, 27
 - treatment for 24–26
- gastroesophageal reflux disease 18
 - diagnosis of 19–21
 - pathophysiology of 19
 - treatment of 19–21
 - treatment options for 29–30
 - endoscopic and surgical management for 29–30
 - pharmacotherapy in 29
- esophageal damage 713
- esophageal dilators 532, 699–700
 - complex strictures 541–543
 - complications 536–537
 - endpoint of 535–536
 - incisional therapy 545
 - inflammation and pills 536
 - medications 536
 - mitomycin C 546–547
 - need for fluoroscopy 535
 - radiation-induced strictures 543–544
 - rule of three 534–535
 - selection of 535
 - self-dilation 547
 - simple strictures 537–541
- size 534
- steroid injection 544–545
- techniques of 534–537
- temporary stent placement 545–546
- timing of 535
- types 533–534
- esophageal diseases 3
 - Barrett's esophagus 230–240
 - BE-related neoplasia 236
 - definition of 230
 - diagnostic challenges 235–236
 - dysplasia and neoplasm 232
 - endoscopic mucosal resection, evaluation of 235
 - endoscopic submucosal dissection specimens 235
 - esophageal cytology specimens, evaluation of 236
 - esophageal mucosal biopsy, diagnosis in 230–235
 - mucosal ablation therapy 235–236
 - squamous cell carcinoma 236–239
 - collagen vascular diseases 227–228
 - Crohn's disease 226
 - cytology of 218
 - dermatologic and collagen vascular diseases 226–227
 - eosinophilic gastroenteritis 225
 - esophagitis 219–220
 - gastroesophageal reflux esophagitis 228–230
 - systemic disease, esophageal involvement in 225–226
- esophageal distension 21
- esophageal diverticula
 - anatomy of 304
 - lower esophageal diverticula (epiphrenic) 304–305
 - mid-esophageal diverticula 304
 - proximal esophageal diverticula 304
 - classification of 304
 - complications of 306
 - definition of 304
 - diagnostic studies for 306
 - contrast esophagogram 306–307
 - esophageal manometry 307
 - esophagogastroduodenoscopy 307
 - ultrasonography 307
 - epidemiology of 304
 - pathophysiology of 305–306

- esophageal diverticula (*cont'd*)
 - physical examination 306
 - post-operative management of 310
 - surgical management for 307
 - cricopharyngeal diverticulum 307–309
 - epiphrenic diverticulum 309–310
 - mid-esophageal diverticulum 309
 - symptoms 305–306
- esophageal dysmotility 115
 - and reflux 313
- esophageal dysphagia 825
 - definition of 6
 - etiologies of 5
- esophageal function testing (EFT)
 - MII-EM (*see* multichannel intraluminal impedance and manometry (MII-EM))
 - multichannel intraluminal impedance
 - for assessment of bolus transit in 174, 178, 179
 - parameters of 177
 - and pH for acid and nonacid gastroesophageal reflux detection 178–184
- esophageal hiatus, myoarchitecture of 360
- esophageal hypersensitivity, 343 *see also* reflux hypersensitivity
 - allodynia 21
 - definition 455
 - esophageal injury, mechanisms of 23
 - hyperalgesia 21
 - mechanism for 448
 - non-pharmacologic therapies for 25–27
 - biofeedback therapy 26
 - cognitive behavioral therapy 26
 - coping skills training 26
 - hypnotherapy 26
 - transmitting healing energy 26
 - pathophysiology of 21–24
 - peripheral and central sensitization in 23
 - pharmacologic therapies for 24–25, 27
 - emerging therapies 25
 - selective serotonin reuptake inhibitors 24–25, 27
 - serotonin and norepinephrine reuptake inhibitors 24–25, 27
 - theophylline 25, 27
 - trazodone 25
 - tricyclic antidepressant 25
 - treatment for 24–26
- esophageal hypervigilance and anxiety scale (EHAS) 24
- esophageal intramural pseudodiverticulosis (EIPD) 135, 138–139, 307
- esophageal leiomyomas 642–643
- esophageal manometry 155, 314, 341–342
 - for esophageal diverticula 307
 - indications for 155
- esophageal motility disorders (EMDs) 265
- esophageal motor function 61
- esophageal mucosa, endoscopic assessment of 338
- esophageal mucosal damage 22
- esophageal muscle and sphincters 4
- esophageal obstruction 771
- esophageal perforation 255
 - Boerhaave syndrome 769, 771
 - clinical features 773
 - definition 769
 - diagnosis 773–774
 - endoscopic management 775–776
 - esophageal obstruction 771
 - etiologies 771
 - iatrogenic perforation 772–773
 - ingestions 771–772
 - management 774
 - pathophysiology 769, 770
 - prognosis 783
 - stent placement 776–783
 - surgical management 774–775
 - traumatic injury 772
- esophageal peristalsis 73, 610–611
 - vagus nerve firing patterns with 75
- esophageal pH-impedance monitoring 194–198
 - clinical relevance of 197
 - interpretation of 195
 - novel impedance metrics 197–198
 - pharyngeal impedance 195–197
 - technical aspects of 194–195
- esophageal pH monitoring systems 188–189
 - catheter-based pH monitoring 189–190
 - clinical relevance of 192–194
 - pH monitoring off therapy 192–193
 - pH monitoring on therapy 193–194
 - proximal pH recordings 190–191
 - wireless pH monitoring 191–192
- esophageal physiology, changes in 805–808
- esophageal pressure topography (EPT) 155, 265
 - beyond Chicago classification 163
 - classify individual test swallows 160–161
 - interpretation of 157–163
 - metrics 159
- esophageal reflux monitoring in asthma 571–572
- esophageal replacement 763
- esophageal stage motor activity
 - deglutitive inhibition 77–78
- esophageal body
 - anatomy 70–71
 - innervation of 70–71
 - smooth muscle in 71
 - striated muscle in 71
 - structure of 70–71
- functional motor activity
 - afferent sensory stimulation 73–74
 - muscle tone 74
 - primary peristalsis 71–73
 - secondary peristalsis 72–73
 - tertiary peristalsis 73
- smooth muscle esophageal body
 - central and peripheral mechanisms, integration of 77
 - central control mechanisms on 74–75
 - intramural myogenic (muscle) control mechanisms 76–77
 - intramural neural control mechanisms 75–77
- esophageal strictures 273, 532–548, 568, 763–764
 - benign 532, 533
 - classification 532–533
 - etiologies 532, 533
 - malignant 532, 534
- esophageal submucosal glands (ESMGs) 377–378
- esophageal symptoms, development of 4
- esophageal tissue resistance, GERD
 - epithelial defense 378–381
 - postepithelial defense 381–382
 - pre-epithelial defense 378

- esophageal webs 539
 - esophagectomy 287, 666, 670
 - for end-stage achalasia 259
 - esophagitis 219–220, 313
 - corrosive esophagitis 224
 - infectious esophagitis
 - bacterial esophagitis 222
 - Candida* esophagitis 220
 - cytomegalovirus esophagitis 221–222
 - herpes esophagitis 220–221
 - pill/drug-related esophagitis 223–224
 - primary eosinophilic esophagitis 224–225
 - primary lymphocytic esophagitis 225
 - radiation-and chemotherapy-induced 222–223
 - esophagitis dissecans superficialis 223
 - esophagocardiomyotomy 284
 - esophagogastric junction (EGJ) 78, 155, 157, 254, 316, 352
 - anatomy of diaphragm 347–348
 - compliance/opening
 - function 369–370
 - 3D pressure topography 361
 - historical perspective 358
 - morphology of 158–159
 - outflow obstruction 161, 166
 - physiologic significance of 363
 - physiology of 348–349
 - sphincter mechanism at 358–360
 - esophagogastric junction outflow
 - obstruction (EGJO) 175–176, 253, 265–266, 268, 287–288, 829–830
 - disorders with 265–267
 - manometric diagnosis of 266
 - pathogenesis and progression of 266
 - esophagogastrroduodenoscopy (EGD), for esophageal diverticula 307
 - esophagography 97, 143
 - esophagomyotomy 284
 - esophagopharyngeal reflexes 69–70
 - esophagopleural fistulae 142
 - esophagus
 - anatomy 3–4
 - normal
 - adventitia 218
 - mucosa 218
 - muscularis propria 218, 219
 - myenteric plexus 219
 - submucosa 218
 - symptoms of 4
 - chest pain 8–9
 - dysphagia 5–7
 - GERD and extraesophageal symptoms 9–10
 - globus 9
 - heartburn and regurgitation 8
 - odynophagia 7–8
 - esophagus, radiology of 114
 - Barrett's esophagus 117, 120–121, 126, 127
 - benign tumors 128
 - adenoma 128
 - duplication cysts 130, 136
 - fibrovascular polyps 129–130, 135
 - glycogenic acanthosis 128–129, 134
 - leiomyomas 129, 135
 - papilloma 128, 134
 - caustic esophagitis 126–127, 133
 - diverticula 135
 - esophageal intramural pseudodiverticula 138–139
 - pulsion diverticula 138
 - traction diverticula 138, 139
 - drug-induced esophagitis 123, 125, 131
 - eosinophilic esophagitis 125, 132
 - esophageal motility disorders 139
 - achalasia 139–140
 - diffuse esophageal spasm 140, 141
 - presbyesophagus 140
 - varices 140–141
 - esophagitis 127
 - fistulae 142–143
 - foreign body impactions 141–142
 - gastroesophageal reflux disease 115
 - infectious esophagitis 121
 - Candida* esophagitis 121–122, 127
 - cytomegalovirus esophagitis 123, 129
 - herpes esophagitis 122–123, 128, 129
 - human immunodeficiency virus esophagitis 123, 130
 - lichen planus 125–126, 132, 133
 - lower esophageal rings 134–135
 - malignant tumors 131
 - esophageal carcinoma 131–134, 136, 137
 - spindle cell carcinoma 134
 - perforation 143
 - radiation esophagitis 126, 133
 - reflux esophagitis 115–116, 123, 124
 - scarring and strictures 116–117, 125, 126
 - technique for 114–115, 122
 - EsophyX[®]-Z+ device *see also* trans-oral incisionless fundoplication (TIF) procedure
 - multiple parts and features of 477
 - traction of tissue 476, 477
 - ethanoic acid 149
 - etidronate 730
 - excessive air swallowing 498–500
 - extensive epithelial necrosis 795
 - external lower esophageal sphincter 359
 - extra-esophageal reflux (EER) 502–503, 554
 - extraesophageal syndromes 554, 556, 567
 - of gastroesophageal reflux disease 337–338
 - extrinsic sphincter 347
 - exudates and inflammation 731
- f**
- feline esophagus 117, 126
 - ferrous sulfate-induced esophagitis 223
 - fiberoptic laryngoscopy 760
 - fibromyalgia (FM) 318
 - fibrositis 318
 - fibrovascular polyps 129–130, 135, 643–644
 - fine-needle aspiration (FNA) 218
 - fistulae 142–143
 - fistulization 743
 - flexible endoscopic evaluation of swallowing (FEES) 817
 - flucytosine (Ancobon) 742
 - fluoxetine 453
 - food bolus 723
 - impactions 713
 - transport 616
 - food dysphagia 532
 - food impactions 721–723, 771
 - foreign body box 719, 720
 - foreign body impactions 141–142

- foreign body ingestion 713–726, 771
 - anatomical considerations 714, 716–718
 - anatomic narrowing 716
 - button batteries 723–724
 - carbon dioxide insufflation 720
 - clinical presentation 717–718
 - complications 726
 - devices 719–721
 - diagnostic evaluation 718–719
 - dishwasher/laundry pods 725–726
 - endoscopic intervention 713
 - endoscopy preparation 719
 - esophageal damage 713
 - esophageal perforations 722, 723
 - exposures 713
 - food boluses 713, 723
 - food impactions 721–723
 - foreign body box 719, 720
 - gastroscope 720
 - hood device 721
 - ingested coins 725
 - magnets 724–725
 - management 719–721
 - narcotic packages 726
 - overtubes 720–721
 - pediatrics 720–722, 724
 - physiological sites 716, 718
 - sedation considerations 719
 - sharp or pointed objects 723
 - small, blunt, rounded objects 725
 - types of 713
 - foreign body reaction 616
 - Forestier disease 822
 - fragmented peristalsis 163, 271, 272
 - treatment of 272–273
 - friction-fit soft caps 148
 - Fuji Intelligent Chromoendoscopy System 149
 - full-thickness endoscopic suturing, for GERD 484–487
 - full-thickness resection device 655
 - functional esophageal disorders *see* functional heartburn (FH); reflux hypersensitivity
 - functional heartburn (FH) 8, 444
 - central neural mechanisms 448
 - clinical presentation 450
 - definition 445–447
 - diagnostic algorithm of 451, 452
 - diagnostic criteria for 446
 - dilated intercellular spaces 449
 - distribution of 459
 - epidemiology 447–448
 - future therapy for 454
 - immunohistochemical nerve fiber identification 449
 - overlap with GERD 458–459
 - pathophysiology 448–450
 - percentage of 447
 - pH-impedance monitoring 451
 - physiological assessment of 445
 - psychological interventions 453
 - psychological therapy 454
 - reflux monitoring 451
 - therapeutic options for 453
 - treatment 451, 453–454
 - upper endoscopy 450
 - functional luminal imaging probe (FLIP) technology 369, 685
 - fundoplication 59, 591–596
 - outcome with 595–596
 - fungal infections 738–743
- g**
- gas reflux 195
 - gastric distention, TLESR 365
 - gastric heterotopia 644
 - gastroesophageal junction (GEJ) 115, 219
 - adenocarcinoma, *H. pylori* 422–423
 - anatomy and physiology 466–467
 - circumferential and axial asymmetry of 361–362
 - crural diaphragm 362–363
 - lower esophageal sphincter 362–363
 - two lower esophageal sphincters 363
 - gastroesophageal reflux disease (GERD) 8, 10, 18, 53, 54, 115, 273, 283, 289, 313, 335, 341, 347, 568 *see also* gastroesophageal reflux disease (GERD)
 - acid, pepsin, and bile acids 376–377
 - ambulatory monitoring for reflux (*see* ambulatory monitoring for reflux)
 - ambulatory reflux monitoring
 - on acid suppression 342–343
 - metrics 340–341
 - phenotypes 341
 - reflux hypersensitivity 341
 - symptoms and ambulatory reflux events 341
 - systems 340
 - with/without acid suppression 340
 - clinical history 336–338
 - clinical spectrum of 336
 - current paradigm of 335–336
 - definition of 188, 335
 - diagnosis of 19–21, 188
 - diagnostic tests for 208
 - advantages of 209
 - bile monitoring 208–209
 - disadvantages of 209
 - mucosal integrity 211–212
 - narrow-band imaging (NBI) 214
 - novel impedance parameters 209–210
 - oropharyngeal pH monitoring 212–214
 - salivary pepsin 210–211
 - endoscopic evaluation 338–339
 - endoscopic suturing for 483–487
 - epithelial barrier 382
 - era of proton pump inhibitor therapy 335–336
 - esophageal peristalsis in reflux disease 370
 - esophageal physiologic testing 341–343
 - esophageal syndromes of 337
 - esophageal tissue resistance
 - epithelial defense 378–381
 - postepithelial defense 381–382
 - pre-epithelial defense 378
 - esophagogastric junction
 - historical perspective 358
 - sphincter mechanism at 358–360
 - esophagus defensive players 377–378
 - and extraesophageal symptoms 9–10
 - extraesophageal syndromes of 337–338
 - FDA-approved endoscopic devices 465
 - gastroesophageal junction
 - circumferential and axial asymmetry of 361–362
 - crural diaphragm 362–363
 - lower esophageal sphincter 362–363
 - two lower esophageal sphincters 363
 - hiatus hernia and reflux disease 368–369
 - H. pylori*
 - and Barrett's esophagus 422
 - epidemiology of 419

- eradication of 421–422
 - esophageal adenocarcinoma 422–423
 - gastroesophageal junction
 - adenocarcinoma 422–423
 - pathobiology of 419–421
 - professional guidelines 423
 - recommendations, and updates 423
 - lower esophageal sphincter
 - compliance/opening function 369–370
 - hypotension 368
 - pathophysiology 19, 465
 - acid burn 382–383
 - cytokine sizzle 384–388
 - phenotypes 338
 - prevalence of 335
 - radiofrequency energy treatment of 467–474
 - relevant comorbid conditions,
 - clinical assessment for 338
 - and sliding hiatus hernias 350–352
 - transient lower esophageal sphincter relaxation
 - antireflux therapy on 368
 - characteristics of 364–365
 - factors modulating 366
 - gastric distention 365
 - neural pathways mediating 366–368
 - pharyngeal mechanisms 365–366
 - trans-oral incisionless fundoplication (TIF) 474–483
 - treatment of 19–21
 - upper gastrointestinal endoscopy 339
 - gastroesophageal reflux disease-health related quality of life (GERD-HRQL) scores 10, 606
 - gastroesophageal reflux disease (GERD),
 - medical management of
 - clinical efficacy
 - erosive esophagitis, healing of 434, 435
 - optimizing PPI efficacy 434–436
 - pH control 434
 - symptom relief 434
 - lifestyle and dietary
 - modifications 428, 429
 - alcohol 430
 - food and weight 430
 - sleep 429–430
 - long-term management 436–439
 - pathophysiologic defects 428
 - pharmacologic therapy
 - acid production 432–433
 - acid-suppressive therapy 432
 - antacids 431
 - baclofen 432
 - H₂-receptor antagonists 433
 - proton pump inhibitors (PPIs) 433–434
 - sucralfate 431
 - recommendations for 439
 - gastroesophageal reflux disease (GERD)-related physiology,
 - aging 809, 810
 - acid suppression 811–812
 - carbohydrate malabsorption 812
 - cardiopulmonary concerns 810
 - changes in 809–811
 - Helicobacter pylori* infection and
 - gastric factors 809–810
 - hepatic cytochrome P450 812
 - lifestyle changes 811
 - medical therapy 811–812
 - obesity 810
 - patient-directed therapy 811
 - proton pump inhibitors 812
 - surgery 813
 - gastroesophageal reflux esophagitis 228–230
 - gastro-gastric plication mechanism of action 484
 - gastrointestinal complications of HIV 737
 - gastropexy 354
 - gastroscope 720
 - genetic syndromes 319
 - Down syndrome 319–320
 - Ehlers-Danlos syndrome 320
 - genodermatoses with esophageal manifestations 799
 - genome-doubled pathway 514
 - GERDx™ device 483
 - giant fibrovascular polyp 135
 - globus 9, 43
 - glycemic control 319
 - glycogenic acanthosis 128–129, 134, 644
 - graft-versus-host disease (GVHD) 227–228, 737
 - granular cell tumors 110, 643
 - ground-glass nuclei 221
- ## h
- heartburn 3, 8, 337
 - Helicobacter pylori* infection
 - and gastric factors 809–810
 - gastroesophageal reflux disease
 - and Barrett's esophagus 422
 - epidemiology of 419
 - eradication of 421–422
 - esophageal adenocarcinoma 422–423
 - gastroesophageal junction
 - adenocarcinoma 422–423
 - pathobiology of 419–421
 - professional guidelines 423
 - recommendations, and updates 423
 - Heller myotomy 13, 30, 254–256
 - vs. pneumatic dilation 286–287
 - vs. POEM 285–286
 - hemangiomas 644
 - hemorrhage 306
 - hereditary amyloidosis 320
 - hernias of Bochdalek 350
 - hernias of Morgagni 350
 - herpes esophagitis 122–123, 128, 129, 220–221
 - herpes simplex virus (HSV) 736–738, 744–748
 - clinical manifestations 744–745
 - complications 744–745
 - cytologic brushings 745
 - diagnosis 745
 - endoscopic mucosal biopsies 745
 - epidemiology 744
 - HSV-1 250
 - pathology 744
 - treatment 745
 - valacyclovir 745
 - hiatus, diaphragmatic, anatomy of 79
 - hiatus hernia
 - diagnosis 352–353
 - and reflux disease 368–369
 - type I 349–350, 354
 - type II and III 350, 354
 - type IV 350, 354
 - high definition-white light endoscopy (HD-WLE) 386
 - high-grade dysplasia 233–234, 236
 - high-resolution esophageal manometry 7

- high-resolution impedance manometry (HRIM) 163–165, 173, 179
 - bolus flow time and esophageal impedance integral 164
 - catheters 156
 - clinical application of 164–165
 - interpretation 164
 - rumination and supragastric belching 165
 - high-resolution manometry (HRM) 65, 155, 252, 272, 273, 278, 351
 - adjunctive or provocative maneuvers 165–167
 - assembly 155–156
 - baseline evaluation 157
 - beyond Chicago classification 163
 - catheter placement for 156–157
 - to gastroesophageal reflux disease 163, 164
 - high-resolution impedance manometry 163–165
 - bolus flow time and esophageal impedance integral 164
 - clinical application of 164–165
 - interpretation 164
 - rumination and supragastric belching 165
 - interpretation of 157–163
 - classify individual test swallows 160–161
 - designation of esophageal motility diagnosis 161–163
 - evaluate EGJ morphology and tone 158–159
 - metrics apply to individual swallows 159–160
 - patient selection and preparation for 156
 - test swallows 157
 - Hill classification 476
 - Hill system 339
 - histamine-2 receptor antagonists 453
 - histoplasmosis 743
 - HIV-related esophageal disorders 749–751
 - Hodgkin's lymphoma 113, 642
 - hood device 721
 - Howell Evans syndrome 798
 - H₂-receptor antagonists, for GERD management 433
 - human immunodeficiency virus esophagitis 123, 130
 - human papillomavirus (HPV) 636
 - humans, duodenogastroesophageal reflux
 - ambulatory bilirubin monitoring 405–408
 - ambulatory pH monitoring 404–405
 - bariatric surgery 410
 - endoscopy 402
 - esophageal aspiration 403
 - gastric measurements 402–403
 - impedance-pH monitoring 408–409
 - scintigraphy 403
 - and symptoms 409–410
 - humoral/cellular immune dysfunction 737
 - hyperalgesia 21
 - hypercontractile (jackhammer) esophagus 28–29, 162, 289
 - hypercontractile peristalsis 269–270
 - treatment of 270–271
 - hyperostotic formations 822
 - hyperplastic squamous epithelium 644
 - hypersensitive esophagus, 183 *see also* reflux hypersensitivity
 - hyperthyroidism 319, 819
 - hypervigilance 23
 - hypnotherapy, for esophageal hypersensitivity 26
 - hypopharynx 97
 - hypothyroidism 319, 819
 - hypoxia-inducible factors (HIFs) 387–388
- i**
- iatrogenic perforation 772–774
 - idiopathic achalasia 249
 - idiopathic EGJOO 266, 267
 - abnormal timed barium esophagram in 267
 - therapy for 267
 - idiopathic esophageal ulcers 8, 750, 751
 - idiopathic inflammatory myopathy 316
 - idiopathic pulmonary fibrosis 573–575
 - idiopathic upper esophageal sphincter dysfunction 821–822
 - imipramine 25, 270
 - immunosuppressive therapy 736
 - impedance parameters 176
 - inadvertent mucosotomy 773
 - incisional therapy 545
 - inclusion body myositis (IBM) 316, 317, 819
 - indefinite for dysplasia 233
 - ineffective esophageal motility (IEM) 163, 175, 592
 - treatment of 272–273
 - ineffective esophageal peristalsis 817
 - infectious esophagitis 8, 121, 220
 - bacterial esophagitis 222
 - Candida* esophagitis 121–122, 127, 220
 - cytomegalovirus esophagitis 123, 129, 221–222
 - herpes esophagitis 122–123, 128, 129, 220–221
 - human immunodeficiency virus esophagitis 123, 130
 - infiltrating adenocarcinoma 137
 - infiltrating carcinomas 133
 - infiltrative disorders 320
 - amyloidosis 320–322
 - sarcoidosis 322
 - infiltrative squamous cell carcinoma 118, 137
 - inflammation 229
 - inflammatory disorders 322
 - Behcet's disease 323
 - Crohn's disease 322–323
 - mast cell disorders 323–324
 - inflammatory mucocutaneous disorders of skin and mucous membranes 789–796
 - inflammatory myopathies *see* myositis
 - ingested coins 725
 - ingestions, food 771–772
 - integrated relaxation pressure (IRP) 159, 161, 166–167, 252–254, 278
 - interstitial cells of Cajal (ICCs) 70, 71
 - intestinal metaplasia 512, 597
 - intraganglionic laminar endings (IGLEs) 70
 - intraesophageal pH control 433, 434
 - hierarchy of 437
 - variability 436
 - intralesional steroid injection 764
 - intraluminal tumor 110
 - intramucosal adenocarcinoma (IMAC) 234
 - intramural esophageal pseudodiverticulosis 836
 - intramural myogenic (muscle) control mechanisms 76–77

intramural neural control
mechanisms 75–77
intramural pseudodiverticulosis 305
intramuscular array endings (IMAs)
70–71
intravenous amphotericin B 742
ion-sensitive field effect transducer
(ISFET) pH electrode 189
irregular esophagus 122
i-SCAN optical enhancement system
149
27-item Mayo Dysphagia
Questionnaire (MDQ) 13
Ivor Lewis technique 287

j

jackhammer esophagus (JE) 28–29,
162, 269–270, 289, 830
treatment of 270–271
jet phenomenon 110
junctional mucosa 512

k

Kearns–Sayre syndrome 46
keratinocyte degeneration 227
ketoconazole 742
kidney transplantation,
immunosuppressive medication
713, 714
Killian–Jamieson diverticulum (KJD)
304, 305
and pouches 106–107, 109, 110
Killian's dehiscence 103, 104
Killian triangle 67
Kochman criteria 544

l

lacunar strokes 815
Laimer's diverticulum 304
Laimer's triangle 70
Lambert–Eaton myasthenic syndrome
(LEMS) 324
lansoprazole, for gastroesophageal
reflux disease 20
laparoscopic anti-reflux surgery (LARS)
465, 467
laparoscopic Heller myotomy (LHM)
256, 283, 284, 827
outcomes of 284
vs. pneumodilation 257
technique 283–284
laparoscopic myotomy 271

laparoscopic Nissen fundoplication
594–596, 599
in reflux hypersensitivity patients
457
laryngeal mucosa 401–402, 555
laryngeal penetration 103
laryngopharyngeal irritation 557
laryngopharyngeal reflux (LPR) 190,
210, 212, 502–503, 554
laryngopharynx 97
lateral pharyngeal pouches and
diverticula 107, 111, 112
lateral proximal cervical esophageal
diverticula 106
lateral proximal cervical esophageal
pouches 106
laundry pod ingestions 725
leiomyomas 129, 135, 642–643
leukoplakia 557, 558
lichenoid lymphocytic infiltration 227
lichen planus (LP) 6, 125–126, 132,
133, 226–227, 539–540, 793–795
with esophageal squamous cell
carcinoma 798
lifestyle and dietary modifications,
GERD management 428, 429
alcohol 430
food and weight 430
sleep 429–430
light scattering spectroscopy 637
LINX sphincter augmentation
device 599, 616
lipid-laden alveolar macrophage index
(LLMI) 569, 570
liquid reflux 195
LOTUS trial 596
Lou Gehrig's disease 821
lower esophageal diverticula
(epiphrenic) 304–305
lower esophageal rings 134–135,
297–298
lower esophageal sphincter (LES), 4,
28, 29, 56, 61, 78, 278, 280, 339,
351, 591, 602, 806, 808 *see also*
gastroesophageal reflux disease
(GERD)
anatomy and innervation 78
central SPG preganglionic fibers
to 80
compliance/opening function
369–370
esophagogastric junction 358–359

functional motor activity 80
diaphragm 82–83
resting/basal pressure 80–82
transient lower esophageal
sphincter relaxations 82
hormones and putative
neurotransmitters on 81
hypotension 368
myoarchitecture of 359
neural control of 362–363
neural pathway to 366
nitroergic innervation of 80
phrenoesophageal membrane of 78
physiologic significance of 363
sympathetic innervation to 80
lower esophageal sphincter-electrical
neuromodulation therapy
(LES-ENT) 619–620
lower motor neural destruction 101
low-grade dysplasia 233
lung transplantation 575–577
lymphadenectomy 666
lymphocytic esophagitis, primary 225
lymphoid hyperplasia 108, 114, 115
lymphoma 113, 120, 121
of base of tongue 121
of palatine tonsil 120
Lyon Consensus 163, 190, 191, 341

m

magnetic sphincter augmentation
(MSA) 273, 592, 602
Barrett's esophagus 615–616
crural diaphragmatic phincter 606
crural repair and evolution of
surgical technique 606–607
crural sphincter restoration 608–610
design safety considerations 605
device migration 617
esophageal acid exposure post
LINX 607, 609
evolution of 606–610
fundoplication 614–615
GERD-HRQL scores 612
hiatal hernia size 606, 615
LES length, reflux barrier 605
LINX implantation 611, 612
LINX sizing 607–608
of lower esophageal sphincter 603–610
manometry studies 613–614
patient-reported quality of life
outcomes 611–612

- magnetic sphincter augmentation (MSA) (*cont'd*)
 - patient selection and evaluation 610–611
 - perioperative complication rates 618
 - perioperative management 611
 - physiologic comparison to fundoplication 605
 - PPIs 614
 - predictors of outcomes 616
 - pressure-release mechanism 604–605
 - reflux control 613
 - reoperation after MSA implantation 618–619
 - reproducibility 614
 - sphincter-augmentation therapy 603–604
 - subjective outcome 613
 - surgical technique and results 605–606
 - surgical training expertise 611
- magnets 724–725, 771
- maintenance therapy 700–701
- major disorders of peristalsis 162
- major motility disorders 267–268
- malignant esophageal cancers 635
 - clinical presentation and diagnosis 637
 - endoscopic treatment 640–641
 - epidemiology 635
 - geographic variation 635
 - historical tobacco use 635
 - metastatic disease 642
 - palliation of dysphagia 641–642
 - pathogenesis 635–636
 - restaging after initial chemoradiotherapy 639–640
 - risk factors 635–636
 - staging 637–639
 - subclassification 640
- malignant melanoma 240
- malignant stenoses 639
- manometry, oropharyngeal dysphagia, evaluation of 45–46
- mast cell activation syndrome (MCAS) 324
- mast cell disorders 323–324
- mastocytosis 324
- matrix metalloproteases (MMP) 513
- mean nocturnal baseline impedance (MNBI) 198, 209, 210, 456
- measure of achalasia disease severity (ADS) questionnaire 13
- mechanical stimulation 21
- mechanical ventilation 737
- medication-induced esophageal injury 728–732, 835
 - antibiotics 730
 - bisphosphonates 730–731
 - chemotherapy-induced esophagitis 732
 - clinical course 729–730
 - clinical features 729
 - diagnosis 729
 - indications 728
 - mechanisms 728–729
 - myocardial infarction 728
 - NSAIDs 731
 - pathology 729
 - with pill-induced injury 731–732
 - prevention 729–730
 - pulmonary embolism 728
 - recognition of 728
 - treatment 729–730
- Meissner's plexus 70
- Mendelsohn's maneuver 47
- meningeal carcinomatosis 101
- mesopharynx 97
- metastatic lymphadenopathy 651, 652
- miconazole (Mycamine) 742
- mid-esophageal diverticulum 304, 309
- migrating motor complex (MMC) 361
- minimally invasive esophagectomy (MIE) 287, 667, 668
- minimally invasive surgery, abdominal laparoscopic approach 827
- minor disorder of peristalsis 162–163
- mitomycin C 546–547
- mitomycin-C injection 765
- mixed connective tissue disease (MCTD) 316, 795
- mixed liquid-gas reflux 195
- modified barium swallow, oropharyngeal dysphagia, evaluation of 44–45
- Montreal classification system 337, 554
- mosapride 273
- motility disorder, 358 *see also* gastroesophageal reflux disease (GERD)
 - medications 587
- motor efferent pathways 42
- mucormycosis 743
- mucosal ablation and suturing of esophageal gastric junction (MASE) 484, 485
- mucosal ablation therapy 235–236
- mucosal disruption of oropharynx and esophagus 737
- mucosal integrity (MI) 209, 211–212, 214
- mucositis 732
- mucous membrane pemphigoid (MMP) 789–791
- multichannel intraluminal impedance (MII) 172, 209
 - for assessment of bolus transit in 174, 178, 179
 - basic principles of 172–173
 - high-resolution impedance manometry 173, 179
 - and manometry 173–174
 - in belching and rumination 176, 178
 - for distal esophageal spasm 175
 - indications for 174
 - for ineffective esophageal motility 175
 - parameters of 177
 - and pH for acid and nonacid gastroesophageal reflux detection 178–184
 - catheter characteristics and placement 180
 - clinical applications 182
 - direct mucosal impedance measurement 183–184
 - interpretation 180–181
 - mucosal integrity, assessment of 182–183
- multichannel intraluminal impedance and manometry (MII-EM) 173–174, 173–175
 - in belching and rumination 176, 178
 - for distal esophageal spasm 175
 - indications for 174
 - for ineffective esophageal motility 175
- multichannel intraluminal impedance with pH (pH-MII) 560, 583
- multiple rapid swallows (MRS) 47, 78, 165, 166

multiple sclerosis (MS) 818–819
 multiple water swallows 165
 multisystem disorders, mucocutaneous
 and esophageal manifestations
 796–799
 muscle tension dysphonia (MTD) 556
 muscle tone 74
 muscular dystrophies 819
 muscularis mucosae 235
 muscularis propria 218, 219
 myasthenia gravis (MG) 324, 820–821
 mycobacterial infections 748
 mycophenylate 732
 myocardial infarction 728
 myositis 316–317

n

narcotic packages 726
 narrow-band imaging (NBI) 149, 214,
 518, 637
 nasogastric intubation 127
 nasogastric tubes (NGTs) 309
 strictures 544
 nasopharynx 97
 National Poison Data System 723
 negative for dysplasia 232
 neoplasia 148
 neoplastic Barrett's cells 513
 neo-squamocolumnar junction 231
 neosquamous epithelium (NSE) 235
 neuromodulators, for reflux
 hypersensitivity 457
 neuromuscular disorders 324–325
 myasthenia gravis (MG) 324
 paraneoplastic syndromes 324–325
 Parkinson's disease (PD) 325
 in pharynx 101–104
 nifedipine 270
 Nissen fundoplication 273, 284,
 594–596, 599, 602
 limitations of 602–603
 nitrates, for esophageal chest pain 29
 nitric oxide (NO) 63–64, 269
 for esophageal chest pain 28
 N-nitroso compounds or nitrosamines
 consumption 636
 nocturnal GERD management 436–437
 non-achalasia esophageal motility
 abnormalities
 esophagogastric junction outflow
 obstruction, disorders with
 265–267
 major disorders of peristalsis
 267–268
 distal esophageal spasm 268–269
 hypercontractile peristalsis 269–270
 minor disorders of peristalsis 271
 fragmented peristalsis 272
 ineffective esophageal motility
 271–272
 nonacid reflux 195
 noncardiac chest pain 337
 non-communicating cysts 130
 non-dysplastic Barrett's esophagus
 (NDBE) 516–517
 AspECT trial 520–521
 chemopreventive agents 520–521
 gastric acid production with PPIs
 and H₂ blockers 520
 medical therapy 519–520
 treatment 519–521
 non-endoscopic cytologic
 techniques 236
 non-erosive reflux disease (NERD) 193,
 400–401
 non-Hodgkin's lymphoma 642
 non-pharmacologic therapies in infants
 and children 584–586
 non-steroidal anti-inflammatory drugs
 (NSAIDs) 123, 731
 normal esophageal squamous (NES) 398
 North American Society for Pediatric
 Gastroenterology and Nutrition
 (NASPGHAN) 724–725
 novel impedance parameters 209–210
 nuclear scintigraphy 582–583
 Nurses' Health Study 628
 nutcracker esophagus (NE) 269, 289
 nutrition 763–764
 nystatin 742

o

obesity 349, 624–629
 abdominal 626
 and aging 810
 and GERD-related complications
 625–626
 GERD-related disorders,
 distributions 624, 625
 and GERD symptoms 625
 mechanical effects 626–628
 non-mechanical effects 628
 observational studies 626
 odynophagia 7–8, 743, 746
 older adults, slower swallowing
 process 44
 omeprazole test 19
 one-size-fits-all approach 336
 open transcervical diverticulectomy
 with CP myotomy 307–308
 optical coherence tomography (OCT)
 153, 519, 637
 oral and pharyngeal motility 99–101
 oral viscous budesonide (OVb) 696
 oropharyngeal candidiasis 737–738
 oropharyngeal dysphagia (OPD) 5,
 39, 813–814
 abnormalities of airway
 protection 38
 abnormalities of bolus transfer 38
 causes of 39–40, 814
 definition of 38
 diet and lifestyle for 49
 endoscopic and surgical
 management 46–47
 etiologies of 5
 evaluation of
 dynamic studies 44
 laboratory tests 44
 manometry 45–46
 modified barium swallow 44–45
 physical examination 44
 ultrasonography 46
 videoendoscopy 45
 general approach 824–825
 management 46
 myriad causes of 38
 pharmacologic treatment 48
 presentation 43–44
 swallowing
 control 41–42
 esophageal phase 40
 mechanisms of 39–41
 musculature 42–43
 oral phase 40
 pharyngeal phase 40
 and postural techniques 47–49
 preparatory phase 40
 symptoms/signs of 39
 oropharyngeal pH monitoring 212–214
 oropharyngeal stage motor activity
 64–70
 oropharyngeal swallow 68
 oropharynx 97
 mucosal disruption 737
 overflow aspiration 103, 104

OverStitch® device 484
oxyntocardiac mucosa 512

P

pain modulators, functional
 heartburn 453
palatine fossae 97, 99
palatine tonsil 110, 113
 lymphoma of 120
panesophageal pressurization 160
papilloma virus 128, 134, 643, 644,
 747–748
paradoxical vocal fold motion
 (PVFM) 503–504
paraesophageal hernia 350, 354
paraneoplastic autoimmune multiorgan
 syndrome (PAMS) 793
paraneoplastic pemphigus 793
paraneoplastic pseudoachalasia 249
paraneoplastic syndromes 324–325
parathyroid adenoma 836
Parkinson's disease (PD) 101, 325,
 816–817
Passavant's ridge 65
Paterson-Brown Kelly syndrome 296
pediatric gastroesophageal reflux 581
 complications 582
 diagnostic approach 581
 diagnostic evaluation 582–584
 epidemiology 581–582
 pathophysiology 581
 pharmacologic therapy 586–587
 surgical fundoplication 587–588
 treatment 584–586
pemphigus vulgaris (PV) 226,
 792–793
peppermint oil, for esophageal chest
 pain 29
pepsin 210–211
 duodenogastroesophageal reflux
 394–396
peptic strictures 116, 125, 537–538,
 832–833
percutaneous endoscopic gastrostomy
 (PEG) 354
perforation 143
peripheral neuropathy 819
peripheral sensitization 341
peristalsis
 breaks 160
 major disorders of 162, 267–268
 distal esophageal spasm 268–269

 hypercontractile peristalsis 269–270
 minor disorders of 162–163, 271
 fragmented peristalsis 272
 ineffective esophageal motility
 271–272
per-oral endoscopic myotomy (POEM)
 30, 271, 288, 309, 773, 827
 for achalasia 258–259, 280–283
 mucosal closure in 282
 mucosal incision in 281
 myotomy in 281–282
 outcomes of 282–283
 vs. pneumatic dilation 283
 submucosal tunneling in 281
 technique 281
 vs. Heller myotomy 285–286
personalized medicine 701
pharmacologic therapy, for GERD
 acid production 432–433
 acid-suppressive therapy 432
 antacids 431
 baclofen 432
 H₂-receptor antagonists 433
 promotility therapy 431–432
 proton pump inhibitors (PPIs) 433–434
 sucralfate 431
pharyngeal lymphomas 113
pharyngeal muscle myopathy 101
pharyngeal peristalsis 65
pharyngeal swallow 67
pharyngoesophageal diverticula 305
pharyngoesophagography 97
pharynx, radiology of 97
 anatomy 97–101
 cervical esophageal webs 108, 110,
 116
 inflammatory conditions 108, 113
 laryngeal cartilages to 99
 neuromuscular disorders in 101–104
 oral and pharyngeal motility
 99–101
pouches and diverticula in 103
 branchial cleft fistulae 107–108
 branchial pouch sinuses
 107–108, 112
 Killian–Jamieson 106–107, 109,
 110
 lateral pharyngeal 107, 111, 112
 Zenker's diverticulum 103–108
tumors
 benign tumors and cysts 110,
 117

 lymphoma 113, 120, 121
 radiation change 113–114, 121
 squamous cell carcinoma
 110–112, 118–120
 webs 108, 110
pH control, for GERD management 434
phosphodiesterase-5 inhibitors 270
photodynamic therapy (PDT) 235,
 541, 640
pH probes 583
phrenic ampulla 358
phrenoesophageal membrane 347
pill-associated esophagitis 223–224,
 771
 etiologies of 8
pill-induced injury 731–732
piriform sinuses 99, 103, 112
plaque-like squamous cell carcinoma 119
pleural effusion 774
Plummer-Vinson-Patterson-Kelly
 syndrome 798
Plummer-Vinson syndrome 296–297,
 637
pneumatic dilation (PD) 29–30,
 255–256, 267, 288
 endoscopic, for achalasia 279–280
 vs. Heller myotomy 286–287
 vs. laparoscopic Heller myotomy
 257
 vs. per-oral endoscopic myotomy
 283
pneumomediastinum 774
pneumothorax 774
POEM *see* per-oral endoscopic
 myotomy (POEM)
poliomyelitis 101
polymyositis (PM) 101, 316, 317, 819
polypoid carcinomas 133
polypoid squamous cell carcinoma
 117, 119, 137
poorly differentiated squamous cell
 carcinoma 239
posaconazole 742
post-ablative strictures 541
post-approval Study (PAS) 606
postcricoid carcinomas 112
postcricoid squamous mucosa 101
post-deglutitive aspiration 43
post-endoscopic therapy
 strictures 541
post-fundoplication side effects
 593–594

- post-operative strictures 542–543
 - post-polio muscular atrophy 101
 - post-reflux swallow induced peristaltic wave (PSPW) 198, 209–210
 - post-reflux swallow-induced peristaltic wave index (PSPWI) 456
 - post-stroke dysphagia 816
 - potassium chloride (KCl) pills 731, 732
 - potassium-competitive acid blockers (P-CABs) 439
 - pre-deglutitive aspiration 43
 - pre-emptive therapy 736
 - premature contraction 28
 - presbyesophagus 140
 - pressurization pattern 160
 - primary amyloidosis 320
 - primary eosinophilic esophagitis 224–225
 - primary esophageal motor disorders, HRM for 156
 - primary esophageal repair 775
 - primary lymphocytic esophagitis 225
 - primary peristalsis 71–73
 - primary ulcerative squamous cell carcinoma 137
 - probe-based CLE 150
 - proliferating cell nuclear antigen (PCNA) 398
 - promotility therapy, for GERD management 431–432
 - propulsion of bolus
 - airway, protection of 65
 - nasal cavity, protection of 65
 - prostaglandin D2 (PGD2) 697
 - proton pump inhibitors (PPIs) 10, 19–21, 53, 188, 193, 224, 280, 313, 315, 335–336, 571, 591, 596, 694–695
 - for GERD management 433–434
 - optimizing PPI efficacy 434–436
 - side effects of 437–438
 - optimizing PPI efficacy 434–436
 - protozoal infections 749
 - proximal esophageal diverticula 304
 - proximal esophageal webs
 - prevalence and etiology of 294–295
 - symptoms and diagnosis of 295
 - treatment of 295–296
 - pseudo-achalasia 252
 - pseudo-reflux 212
 - pseudo-Zenker's diverticulum 106
 - pulmonary and otolaryngologic manifestations of GERD in aging 810
 - pulmonary complications, GERD
 - asthma and GERD 570–573
 - clinical presentations and evaluation 569–570
 - idiopathic pulmonary fibrosis 573–575
 - lung transplantation 575–577
 - pathophysiology 567–569
 - therapy 570
 - pulmonary embolism 728
 - pulmonary function test (PFT) findings 570
 - pulsion diverticula 138
 - purinergic receptors (P2X) 22
 - pyrosis 8
- q**
- quality of life (QoL) 3, 10–13
 - symptom and assessment tools 10–13
 - quinidine 732
 - QX-314 25
- r**
- rabbit esophageal mucosa, transmission electron micrographs 400–401
 - rabeprazole, for gastroesophageal reflux disease 20
 - radiation edema 114
 - radiation esophagitis 126, 133
 - radiation fibrosis 114
 - radiation-induced esophagitis 222–223
 - acute esophagitis 222
 - radiation-induced strictures 543–544
 - radiation therapy 656, 737
 - radiofrequency ablation (RFA) 235, 522–523, 541, 656
 - randomized controlled trials (RCTs) 816
 - ranitidine 457
 - RAP *see* resection and plication (RAP) technique
 - rapid-drink challenge test 165, 166
 - recombinant hemoglobin (rHb) 269
 - reflexive pharyngeal 40
 - reflex therapy 567
 - reflux esophagitis 115–116, 123, 124, 228
 - with granular mucosa 123
 - with inflammatory esophagogastric polyp 124
 - with thickened folds 124
 - with ulceration 124
 - reflux finding score (RFS) 557–559
 - reflux hypersensitivity 214, 341, 444
 - clinical presentation 456–457
 - definition of 454–455
 - diagnosis 457
 - diagnostic algorithm of 451, 452
 - diagnostic criteria for 455
 - distribution of 459
 - epidemiology 455
 - overlap with GERD 458–459
 - pathophysiology 455–456
 - percentage of 447
 - psychological interventions 458
 - therapeutic options for 458
 - treatment 457–458
 - reflux monitoring in IPF 573–575
 - reflux of acid/nonacid gastric contents 554
 - reflux symptom index (RSI) 558, 559
 - reflux testing 583
 - and lung transplantation 575–576
 - reflux theory 567, 570
 - refractory GERD 444
 - refractory heartburn 444
 - refractory strictures 544
 - regurgitation 8, 337
 - repetitive retrograde contractions 254
 - repetitive swallowing 815
 - resection and plication (RAP) technique 486
 - residual Barrett's esophagus (BE) 656
 - Restech Dx-pH Measurement System 212, 213
 - Restech™ system 191
 - resting/basal pressure, to lower esophageal sphincter 80–82
 - retention cysts 110, 117
 - Rigiflex balloon 255
 - ringed esophagus 125, 132
 - rings, definition of 294
 - Rome IV functional esophageal disorders 444, 445
 - rumination syndrome 53, 501–502
 - clinical presentation of 53
 - definition of 53
 - demographic characteristics of 53
 - diagnosis of 55

- rumination syndrome (*cont'd*)
 - differential diagnosis for 53–54
 - manometric pattern of 55
 - pathophysiology of 54–55
 - Rome IV criteria of 53
 - treatment of
 - biofeedback therapies 56
 - diaphragmatic breathing 55–56
 - fundoplication 59
 - medical therapy 56–57
 - psychologic approaches 56
- “R” wave 55, 178
- S**
- saccular cysts 110
- salivary pepsin 210–211, 214
- sarcoidosis 322
- Savary-Gilliard dilators 297
- Schatzki rings 134, 135, 138, 294, 298–300, 352, 538–539
 - epidemiology of 298
 - pathogenesis of 298
 - pathology of 298
 - presentation and diagnosis of 298–299
 - treatment of 299–300
- scintigraphy 569
 - duodenogastroesophageal reflux 403
- scleroderma 227, 312–316, 796–797, 830–831
- secondary (AA) amyloidosis 320
- secondary esophageal motor disorders, HRM for 156
- secondary peristalsis 72–74, 78
- selective serotonin reuptake inhibitors (SSRIs) 457–458
 - for esophageal hypersensitivity 24–25, 27
- self-dilation 547
- self-expandable metal stents (SEMS)
 - for palliation of malignant esophageal strictures 641
- self-expanding stents (SESS) 827
- sensory afferent pathways 41
- serologic testing 738
- serotonin and norepinephrine reuptake inhibitors, for esophageal hypersensitivity 24–25, 27
- shaggy esophagus 122, 128
- Shaker exercise 48
- Short Form (SF)-36 10, 13
- sicca symptoms 317
- sigmoid esophagus 139
- sildenafil, for esophageal chest pain 29
- simple strictures 537–541
- single nucleotide polymorphisms (SNPs) 692
- 60 seconds rule, for diaphragmatic hiatus assessment 476
- Sjogren’s syndrome (SS) 317–318
- Sleep, and GERD management 429–430
- sliding hiatus hernias 349
 - diagnosis 352
 - endoscopic image of 352, 353
 - and reflux disease 350–352
 - therapy 353–354
- sloughing esophagitis 223, 836
- slow waves 76
- small-caliber esophagus 125
- small cell carcinoma 239–240
- smooth muscle esophageal body 74–77
 - central and peripheral mechanisms, integration of 77
 - central control mechanisms on 74–75
 - intramural myogenic (muscle) control mechanisms 76–77
 - intramural neural control mechanisms 75–77
- smooth muscle relaxants 254
- solid food dysphagia 532
- solid organ transplantation 737
- solid test swallows 166
- Sonic hedgehog (SHH) 513
- spastic esophageal motility abnormalities 268
- specialized columnar epithelium 512
- specialized intestinal metaplasia 512
- spindle cell carcinoma 134
- spindled or sarcomatoid squamous cell carcinoma 237
- splanchnic nerves 4
- spontaneous esophageal rupture 769
- spontaneous hemorrhage 836
- spontaneous intramural hematoma of the esophagus 836
- squamocolumnar junction (SCJ) 347
- squamous cell carcinoma 110–112, 118–120, 133–134, 236–239
 - infiltrative 118
 - plaque-like squamous 119
 - polypoid 119
 - of posterior pharyngeal wall 112
 - radiographic findings of 110
 - ulcerative 118
- squamous hyperplasia 228
- squamous-lined ducts 218
- squamous papillomas 128, 134, 643, 644
- steakhouse syndrome 295, 298
- stent placement 765, 776–783
- steroid injections 544–545
- steroids 763
- Stevens Johnson syndrome (SJS) 795
- Stretta® procedure, for GERD treatment
 - endoscopic appearance 471
 - in altered anatomy 468–469
 - mechanisms of action 467–468
 - patient selection 468
 - radiofrequency generator for 469
 - safety and clinical outcomes 471–474
 - single-use RF energy catheters 469
 - technical considerations 469–471
- strip biopsy 652
- stroke 814–815
 - rehabilitation 815
- subcutaneous emphysema 773, 774
- submucosal glands 218
- sub-squamous intestinal metaplasia (SSIM) 524
- sucralfate, for GERD management 431
- superficial layering of eosinophils 224
- superficially invasive esophageal squamous cell carcinoma 237
- superficial spreading carcinoma 132, 136
- supine liquid swallow protocol 157
- supragastric belching (SGB) 500–501
- supraglottic cancers 111
- supraglottic swallow 47
- surgical esophageal myotomy, for achalasia 283–287
 - Heller myotomy vs. pneumatic dilation 286–287
 - Heller myotomy vs. POEM 285–286
 - outcomes 284–285
 - technique 283–286
- surgical fundoplication 587–588
- surgical treatment for esophageal cancer 661–672
 - cardiovascular function 665
 - clinical staging 671
 - clinical TNM classification 662
 - cM evaluation 663, 664

- cN evaluation 663
- cT evaluation 663
- diagnosis and screening 661
- digestive tract continuity
 - reconstruction 666–667
- endoscopic ultrasonography 662
- flexible videoesophagoscopy 661
- liver function 665
- morbidity and mortality 668–669
- neo-adjuvant therapy 669–670
- perioperative care 667–668
- physiological status, preoperative
 - assessment 663–665
- positron emission tomography
 - scan 663, 664
- pragmatic therapeutic strategy 670–671
- preoperative composite risk score
 - and nomograms 665
- primary tumor resection 665–666
- pulmonary function 664–665
- quality of life 669
- recurrence 669
- regional lymph node
 - classification 662
- respiratory complications 664–665
- staging 661–664
- swallow-associated peristalsis 352
- swallowing 61–62, 68, 99
 - central organizing center 41
 - control 41–42
 - esophageal phase 40
 - mechanisms of 39–41
 - motor efferent pathways 42
 - multichannel intraluminal
 - impedance, classification by 174–175, 177
 - musculature 42–43
 - oral phase 40
 - organizational structure and
 - function 62–64
 - cortical and supramedullary influences 64
 - motor function 63
 - organization 63–64
 - sensory 63
 - oropharyngeal stage motor activity 64–70
 - pharyngeal phase 40
 - phases of 99, 102
 - and postural techniques 47–49
 - cost-effectiveness 48–49
 - against laryngeal restriction 48
 - maneuvers and exercises 47–48
 - Mendelsohn's maneuver 47
 - multiple swallows 47
 - Shaker exercise 48
 - supraglottic swallow 47
 - preparatory phase 40
 - propulsion of bolus 65
 - airway, protection of 65
 - nasal cavity, protection of 65
 - sensory afferent pathways 41
 - swallowing pattern generator (SPG) 62
 - structure of 62
 - transmitter mechanisms 63
 - swallowing against laryngeal
 - restriction (SALR) 48
 - swallowing pattern generator (SPG) 62
 - structure of 62
 - transmitter mechanisms 63
 - swallowing quality of life questionnaire (SWAL-QOL) 13
 - symptom association probability (SAP) 20
 - systemic diseases, esophageal
 - involvement in 312
 - connective tissue disorders
 - fibromyalgia (FM) 318
 - mixed connective tissue disease (MCTD) 316
 - myositis 316–317
 - Sjogren's syndrome (SS) 317–318
 - systemic lupus erythematosus (SLE) 318
 - systemic sclerosis (scleroderma) 312–316
 - endocrine disorders 318
 - diabetes mellitus (DM) 318–319
 - thyroid disease 319
 - genetic syndromes 319
 - Down syndrome (DS) 319–320
 - Ehlers-Danlos syndrome (EDS) 320
 - infiltrative disorders 320
 - amyloidosis 320–322
 - sarcoidosis 322
 - inflammatory disorders 322
 - Behcet's disease (BD) 323
 - Crohn's disease (CD) 322–323
 - mast cell disorders 323–324
 - neuromuscular disorders 324–325
 - myasthenia gravis (MG) 324
 - paraneoplastic syndromes 324–325
 - Parkinson's disease (PD) 325
 - systemic immune-modifying
 - therapy 317
 - systemic lupus erythematosus (SLE) 318, 797
 - systemic sclerosis (scleroderma) 312–316, 796–797
 - with esophageal adenocarcinoma 797
- t**
 - tailored fundoplication 592–593
 - T-cell dependent immunological
 - attack 820
 - tegaserod 453
 - temporary stent placement 545–546
 - tertiary peristalsis 73
 - tetracycline 123, 730
 - theophylline, for esophageal
 - hypersensitivity 25, 27
 - thermal/laser diverticulotomy with
 - cricopharyngotomy 308
 - thoracoscopy 667
 - thoracotomy 667
 - three-incision McKeown technique 287
 - thyroid disease 319, 819
 - tight junctions (TJs) 378–380
 - timed barium esophagram (TBE) 267
 - tissue sealants 782
 - TLESR *see* transient lower esophageal
 - sphincter relaxation (TLESR)
 - T lymphocytes 229
 - topical, or swallowed, corticosteroids
 - (tCS) 696–697
 - Toupe fundoplication 827
 - toxic epidermal necrolysis (TEN) 795
 - traction diverticula 138, 139, 305
 - transcranial magnetic stimulation
 - (TMS) 64
 - transhiatal approach 667
 - transient LES relaxation (TLESR) 342, 349, 351
 - transient lower esophageal sphincter
 - relaxation (TLESR) 82, 570
 - antireflux therapy on 368
 - characteristics of 364–365
 - factors modulating 366
 - gastric distention 365
 - neural pathways mediating 366–368
 - pharmacologic agents targeting 368
 - pharyngeal mechanisms 365–366
 - transient receptor potential vallinoid
 - receptors (TRPV) 22

- transient receptor potential vanilloid-1 (TRPV1)-positive nerve fibers 456
 - transition zone 72
 - transluminal washout and
 - debridement of extraluminal contamination 782
 - transmission electron microscopy (TEM) 382
 - transmitting healing energy, for
 - esophageal hypersensitivity 26
 - trans-oral incisionless fundoplication (TIF) procedure 592
 - applications for 482–483
 - and concomitant laparoscopic hernia repair 481–482
 - mechanisms of action 474–475
 - in obese patients 483
 - patient selection 476
 - post-per-oral endoscopic myotomy (POEM) 482–483
 - safety and clinical outcomes 479–481
 - technical considerations 476–479
 - transpyloric feeding 586
 - transthoracic approach 667
 - transthyretin (TTR) 320
 - traumatic injury, esophagus 772
 - trazodone 270
 - for esophageal hypersensitivity 25
 - Treponema pallidum* 749
 - tricyclic antidepressants (TCAs) 289
 - for esophageal hypersensitivity 25
 - functional heartburn (FH) 453
 - trisomy 21 *see* Down syndrome (DS)
 - true soft tissue tumors 110
 - tunneling technique 655
 - tylosis with esophageal cancer (Howell Evans syndrome) 798
- u**
- ulcerative squamous cell carcinoma 118
 - ultrasonography
 - for esophageal diverticula 307
 - oropharyngeal dysphagia, evaluation of 46
 - unilateral pharyngeal paresis 101, 103
 - unresectable esophageal cancer 641–642
 - uphill varices 140, 141
 - upper endoscopy with biopsy of
 - esophagus 584
 - upper esophageal sphincter (UES) 4, 28, 40, 45, 46, 61, 104, 295
 - anatomy and innervation 65–67
 - dysfunction 539
 - functional motor activity 67
 - basal pressures 67
 - esophagopharyngeal reflexes 69–70
 - swallowing 68
 - muscular elements 67
 - and pharynx 805
 - upper gastrointestinal endoscopy 338, 339
 - upper gastrointestinal radiography (UGI) 582
 - upright swallows 165
 - US Consumer Products Safety Commission (CPSC) 724–725
- v**
- varicella zoster virus 747
 - varices 140–141
 - varicoid carcinomas 133
 - vascular compression 834–835
 - vascular endothelial growth factor (VEGF) 513
 - venlafaxine 458
 - ventral swallowing group (VSG) 62
 - verrucous carcinoma 237
 - videofluoroscopic evaluation 820
 - vigorous achalasia 250
 - viral infections 744–748
 - viscero-visceral hyperalgesia 23
 - viscous test swallows 166
 - viscerco-somatic convergence 23
 - vocal cord dysfunction (VCD) 503–504
 - volumetric laser endomicroscopy (VLE) 150–153, 519
 - vonoprazan 439
 - voriconazole 742
- w**
- water swallowing test 817
 - weakly acidic reflux 195, 197
 - weakly alkaline reflux 195
 - webs, definition of 294
 - weight loss as GERD treatment 628–629
 - well-differentiated squamous cell carcinoma 239
 - whole-exome sequencing of DNA, BE 513
 - wireless pH monitoring 191–193
 - benefit of extended duration of recording 192
 - catheter and capsule 192
 - technical aspects of 191–192
 - tolerability and complications of 192
- x**
- xerostomia 44
- z**
- Zenker's diverticulum 47, 67, 97, 103–108, 296, 304, 305, 307, 822–824
 - contour deformities in 105
 - contrast esophagogram for 307
 - esophagogastroduodenoscopy for 307
 - Killian's dehiscence 103, 104
 - pharyngeal regurgitation from 105
 - ultrasonography for 307
 - Zenker's per-oral endoscopic myotomy (Z-POEM) 308

